As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in ...

Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

Once-weekly semaglutide 1 mg was tied to a reduction in total daily insulin dose among adults with type 1 diabetes, ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...

Semaglutide 2.4 mg improves insulin sensitivity and glycemic outcomes in adolescents with obesity, according to a secondary analysis of STEP TEENS.

Intervention used once-weekly subcutaneous semaglutide or placebo for 30 weeks with an eight-week titration to 1.0 mg or highest tolerated dose. Visits and assessments took place primarily in ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...